Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

14.34 +0.73 (+5.36%)
Streaming Delayed Price Updated: 1:59 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,000,073
Open 13.81
Bid (Size) 14.32 (5)
Ask (Size) 14.36 (1)
Prev. Close 13.61
Today's Range 13.73 - 14.71
52wk Range 10.57 - 33.33
Shares Outstanding 121,640,069
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
From Denali Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
-31.2%
-31.2%
1 Month
+2.5%
+2.5%
3 Month
-13.1%
-13.1%
6 Month
-39.0%
-39.0%
1 Year
-41.2%
-41.2%

More News

Read More
What Happened To Denali Therapeutics Stock Wednesday?
Via Benzinga
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback
Via Benzinga
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
Why Is Denali Therapeutics Stock Trading Higher On Wednesday?
Via Benzinga
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Via Benzinga
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.
Via Investor's Business Daily
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
Via Benzinga
This Denali Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Friday
Via Benzinga
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Stock Is Sliding After The Bell: Here's Why
Via Benzinga
A Biotech Breakout Will Be Led By Small Caps
Via Talk Markets
Topics Artificial Intelligence Economy
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following
From Denali Therapeutics Inc.
Via GlobeNewswire
DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Stock Gets Technical Rating Upgrade
Via Investor's Business Daily

Frequently Asked Questions

Is Denali Therapeutics Inc. - Common Stock publicly traded?
Yes, Denali Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Denali Therapeutics Inc. - Common Stock trade on?
Denali Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Denali Therapeutics Inc. - Common Stock?
The ticker symbol for Denali Therapeutics Inc. - Common Stock is DNLI on the Nasdaq Stock Market
What is the current price of Denali Therapeutics Inc. - Common Stock?
The current price of Denali Therapeutics Inc. - Common Stock is 14.34
When was Denali Therapeutics Inc. - Common Stock last traded?
The last trade of Denali Therapeutics Inc. - Common Stock was at 07/30/25 01:59 PM ET
What is the market capitalization of Denali Therapeutics Inc. - Common Stock?
The market capitalization of Denali Therapeutics Inc. - Common Stock is 1.74B
How many shares of Denali Therapeutics Inc. - Common Stock are outstanding?
Denali Therapeutics Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.